A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20124 in Patients with Advanced Solid Tumors
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs HS 20124 (Primary)
- Indications Carcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company; Shanghai Hansen Biomedical Technology
- 22 Jan 2025 New source identified and integrated China Drug Trials (CTR20243578).
- 22 Jan 2025 Highest patient count added from Chinese Clinical Trial Register.
- 13 Jan 2025 New trial record